GlassScriptPhysician profile
Ashley Y Denton
NPI 1932666252
$10,108.98
in general payments reported to CMS, 2019-2025
59 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $1,772 · 2023: $2,370 · 2024: $2,795 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,009 · Education: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,008.70 |
| Education | $507.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $875.53 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $858.63 | 2022-2025 | |
| Abbvie INC. | $827.55 | 2021-2025 | |
| Incyte Corporation | $812.46 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $684.32 | 2021-2025 | Tecvayli, Erleada, Balversa |
| Merck Sharp & Dohme LLC | $633.76 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $445.35 | 2021-2025 | Ninlaro, Fruzaqla, Iclusig |
| Regeneron Healthcare Solutions, INC. | $435.74 | 2022-2025 | Libtayo |
| Exelixis INC. | $423.55 | 2021-2025 | Cabometyx |
| Eisai INC. | $340.02 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $218.51 | 2021-2025 | Onivyde, Tazverik, Somatuline Depot |
| Glaxosmithkline, LLC. | $182.85 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $178.90 | 2022-2024 | |
| Pfizer INC. | $171.57 | 2023-2025 | |
| Lilly USA, LLC | $162.68 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $153.72 | 2022-2023 | Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $143.85 | 2022-2024 | Opdivo |
| Amgen INC. | $136.06 | 2022-2023 | Lumakras, Prolia, Evenity |
| Puma Biotechnology, INC. | $135.91 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $135.82 | 2022-2025 | Fotivda |
| Seagen INC. | $123.60 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Mirati Therapeutics, INC. | $117.61 | 2023 | Krazati |
| Intera Oncology, INC | $107.69 | 2024 | Intera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.29 | 2022-2024 | Gilotrif |
| Sobi, INC | $102.93 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.08 | 2021-2025 | |
| Genentech USA, INC. | $99.12 | 2023-2024 | Phesgo, Alecensa, Hemlibra |
| Pharmacyclics LLC, An Abbvie Company | $98.58 | 2022-2023 | Imbruvica |
| Array Biopharma INC | $90.34 | 2022-2025 | Mektovi, Lorbrena, Braftovi |
| Pharmaessentia USA Corporation | $86.27 | 2022-2024 | Besremi |
| Emd Serono, INC. | $82.33 | 2024 | |
| Adc Therapeutics America, INC. | $77.65 | 2021-2023 | |
| Deciphera Pharmaceuticals INC. | $77.03 | 2024-2025 | Qinlock, Romvimza |
| Astrazeneca Pharmaceuticals LP | $72.35 | 2021-2022 | |
| Beigene USA, INC. | $66.35 | 2021-2025 | Brukinsa |
| Tersera Therapeutics LLC | $62.59 | 2021-2025 | Zoladex |
| Iovance Biotherapeutics, INC. | $61.79 | 2024-2025 | Amtagvi |
| Beone Medicines USA, INC. | $58.04 | 2025 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $56.22 | 2022-2023 | Provenge |
| Pharmacosmos Therapeutics INC. | $47.21 | 2023-2024 | Cosela, Monoferric |
| Kyowa Kirin, INC. | $43.30 | 2023-2025 | Poteligeo |
| Stemline Therapeutics INC. | $42.58 | 2023 | Orserdu |
| Kite Pharma, INC. | $41.33 | 2023 | Yescarta |
| G1 Therapeutics, INC. | $38.82 | 2022-2023 | Cosela |
| Apellis Pharmaceuticals, INC. | $30.29 | 2023 | Empaveli |
| Caris Mpi, INC. | $29.49 | 2025 | Mi Cancer Seek |
| Alnylam Pharmaceuticals INC. | $29.37 | 2025 | Givlaari |
| Geron Corporation | $28.58 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $22.44 | 2025 | Beleodaq |
| Tempus Ai, INC | $20.12 | 2024 | |
| Lundbeck LLC | $18.44 | 2021 | |
| Novocure INC. | $17.73 | 2023 | Optune |
| Alexion Pharmaceuticals, INC. | $17.08 | 2023 | Ultomiris |
| Axonics, INC. | $17.02 | 2022 | |
| Servier Pharmaceuticals LLC | $14.86 | 2021 | |
| Morphosys, US INC. | $13.98 | 2023 | Monjuvi |
| Avanir Pharmaceuticals, INC. | $11.94 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.54 | 2021 | |
| Rigel Pharmaceuticals, INC. | $8.22 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Denton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.